Diabetes News

 2017-11-29
Medtronic 780G Receives FDA Approval

Medtronic’s MiniMed 780G Receives FDA Approval 


The FDA has approved Medtronic’s MiniMed 780G, the newest automated insulin dosing (AID) system on the market. MORE
Baqsimi acquired

Eli Lilly’s Baqsimi Acquired by Amphastar: What This Means for People With Diabetes


Eli Lilly’s nasal glucagon, Baqsimi, has been acquired by Amphastar. Here’s what you should know about the change and its significance.MORE

Mark Cuban’s Cost Plus Drugs Makes Diabetes Products More Affordable


Mark Cuban's Cost Plus Drugs Company just announced that they offer Janssen's Invokana, Invokamet and Invokamet XR for type 2 diabetes.MORE

Why Diabetes Should be Screened by Age Instead of Weight


Many cases of diabetes may be missed by screening only by weight instead of age, especially for some racial and ethnic groups.MORE
Civica

California Partners with Civica Rx to Make More Affordable Insulin 


California has signed a contract with Civica Rx to make more affordable insulin for Americans with diabetes. Here’s what you should know about their partnership, CalRx.MORE

Sanofi to Slash Price of Lantus by 78%, Cap Out-of-Pocket Costs to $35


Sanofi has capped monthly out-of-pocket costs for Lantus to $35 for all with commercial insurance and will cut the price of Lantus by 78%, effective January 1, 2024. MORE

Novo Nordisk to Slash Insulin Prices by over 65%


Novo Nordisk announced that starting January 1st, 2024 they will be lowering the list price of several of their insulins by 65-70%.MORE
Freestyle Libre 2 & 3 Receive FDA Clearance for Integration with Automated Insulin Delivery Systems

Freestyle Libre 2 and 3 Receive FDA Clearance for Integration with Automated Insulin Delivery Systems


Abbott, makers of the Freestyle Libre 2 and 3, modified their sensors to enable integration with automated insulin delivery systems. Here’s what you should know!MORE

$25 List Price + $35 Copay Caps: Lilly’s New Insulin Cost Reductions


On March 1, 2023, insulin manufacturer Lilly announced expanded insulin cost-saving measures for people with and without health insurance coverage.MORE

FDA Approves Teplizumab to Delay Onset of Type 1 Diabetes


Teplizumab binds to certain immune system cells and delays the progression of T1D.MORE

This New App is Designed to Make Tracking Your Insulin Easier


If you use Lilly brand insulin, this new connected platform is designed to make tracking your diabetes data a lot easier. MORE

Say Hello to BeyondType2.org in French, German and Italian!


BeyondType2.org now offers critical resources in five languages for people living with and impacted by type 2 diabetes.MORE
ADA2022

The Future of Insulin — Will It Be Affordable for the People Who Need It?


Research is showing promising advancements with new weekly oral and injectable insulins—but will they actually be affordable?MORE
ADA2022

Diabetes + Dementia: Using Nasal Insulin to Improve Brain Function


With rising rates of obesity in both type 1 and type 2 diabetes, understanding the impact on long-term brain health and function is critical.MORE
ADA2022

Women + Exercise: It’s Complicated


Women living with type 1 diabetes are told exercise will help better manage their diabetes. That’s easier said than done. MORE
ADA2022

Reaching Everyone — Health Disparities in Physical Activity


People living with diabetes are told to just exercise more to better manage their diabetes. Here is why its not that simple. MORE
ADA2022

Another Reminder that Racial/Ethnic Inequality Exists in Diabetes Care


Despite the variety of diabetes medications and technology, race and ethnicity still weigh heavily on a person’s access to these life-saving tools.MORE
ADA2022

Race, Racism, and Diabetes Research


Diabetes care and research is still drastically impacted by racist practices. It’s time to call the racism out. MORE
ADA2022

Mounjaro: Its Powerful Potential to Treat Type 2 Diabetes & Obesity


Experts discuss the impressive impact and future potential of using Mounjaro (tirzepatide) to treat obesity and type 2 diabetes.MORE
ADA2022

Research: Practical Use of Closed-Loop Insulin Pumps


Closed-loop insulin pump technology is a game-changer for those taking insulin. Here are essential tips to using them in day-to-day life.MORE
ADA2022

Access to Insulin: In the United States


Despite the growing variety of insulin and technology, access to this life-saving drug continues to be a dire problem in the United States.MORE
ADA2022

Access to Insulin: In Low-Income Countries


In many countries, a person with diabetes may walk for four days to get a vial of short-acting insulin and seven to 10 days for long-acting.MORE
tirzepatide weight loss research

Promising New Drug Leads to 22.5% Weight Loss in Adults Living with Obesity


The latest study on a new drug is making headlines for its impressive ability to help patients lose weight.MORE

Stem Cell Therapy for Type 1 Diabetes: Patient Achieved Insulin Independence on Day 270


A patient in the Vertex Pharmaceutical’s clinical trial using stem-cell therapy to treat type 1 diabetes has achieved insulin independence on Day 270 of the trial. MORE

Coverage of Dexcom G6 CGM Now Improved with TRICARE


TRICARE healthcare members can now receive the Dexcom G6 continuous glucose monitor (CGM) under pharmacy benefits.MORE
insulin copays

The Affordable Insulin Now Act: A Step Toward Federal Legislation


The Affordable Insulin Now Act, if passed in its current form, could help bring down the cost of insulin for millions of insured people with diabetes.MORE

FreeStyle Libre 2 Now More Easily Accessible for Military Members Through TRICARE


Military members with TRICARE now have easier access to Abbott’s FreeStyle Libre 2 continuous glucose monitor (CGM).MORE
Dexcom Breakthrough Device Designation

COVID-19 Pushes FDA Approval of Breakthrough Device Designation for Dexcom CGM in Hospital Settings


The FDA has granted Breakthrough Device Designation for Dexcom CGM in hospital settings after the pandemic highlighted essential care needs for patients with diabetes.MORE
Eversense E3

Eversense E3 Continuous Glucose Monitor Gains FDA Approval, Offers Extended Wear-Time


The Eversense E3 continuous glucose monitor (CGM) is an exciting advancement for the diabetes community, with improved wear-time and accuracy.MORE

Omnipod 5 Receives FDA Approval


Omnipod 5, a closed-loop tubeless insulin pump with smartphone control that integrates with the Dexcom G6 continuous glucose monitor, has now received FDA approval.MORE
Drug Pricing Investigation

Inside the Drug Pricing Investigation from the House Oversight and Reform Committee


The results of the most recent report from the committee make things clear for the United States — the need for access to affordable healthcare is direr than ever.MORE

The Potential Impact of Build Back Better on American Healthcare


Dive into the basics of Build Back Better, why people with diabetes should follow the bill as it progresses, and the impact it could have on your health.MORE
Mark Cuban Pharmacy

Mark Cuban’s New Online Pharmacy Provides Affordable Access to Some Common Prescription Drugs


Mark Cuban's latest investment in the pharmaceutical industry offers common generic prescription medications (not including insulin) at a fraction of the cost.MORE

A Win for T1D in California: Senate Bill 97 Signed Into Law


The bill requires type 1 diabetes informational materials to be developed for the parents and guardians of pupils in California schools.MORE

Beyond Type 1 Launches Web Platform in Arabic 


Diabetes information, stories, and news are now available in Arabic at ar.beyondtype1.org.MORE

COVID-19 Vaccines For Kids Ages 5 to 11 With Diabetes: What to Know


COVID-19 vaccines are now available for kids age 5+! Learn about safety and managing side effects for kids with type 1 diabetes.MORE
vertex pharmaceuticals stem cell therapy for type 1 diabetes

Stem-Cell Therapy for Type 1 Diabetes Reduced Patient’s Insulin Needs by 91%


The early results of a clinical trial using stem-cell therapy to treat type 1 diabetes reduced the patient’s insulin needs by 91%.MORE

Lilly Announces Lower List price for Insulin Lispro


The company will lower the list price of the generic version of Humalog in the U.S. by an additional 40 percent starting January 1, 2022.MORE

Lilly Issues Voluntary Nationwide Recall of One Lot of Glucagon Emergency Kit


Lilly announced the voluntary recall of lot D239382D, Expiration April 2022 of Glucagon Emergency Kits.MORE
Latinx Diabetes Initiative

The Latinx Diabetes Initiative Provides Culturally Tailored Care To Latinx Patients With Diabetes


Andreina Millan Ferro is centering culturally sensitive diabetes care for Latinx patients with diabetes at the Latinx Diabetes Initiative.MORE
Yarishdy Mora

Yarishdy Mora Is Empowering Youth Through Diabetes Education In Mexico


Yarishdy Mora is the director of the Youth Health Program for Project HOPE in Mexico. She creates platforms that help youth learn about diabetes. MORE
Screened for Type 2 Diabetes

Overweight Adults to Now Be Screened for Type 2 Diabetes At 35


The U.S. Preventive Services Task Force now recommends overweight and obese adults to get screened for Type 2 diabetes at the age of 35.MORE
pandemic homelessness

Pandemic Homelessness Disproportionately Impacts People With Diabetes


An American Diabetes Association report found that pandemic homelessness hit people with diabetes 48 times harder.MORE
Freestyle Libre 2

Abbott’s FreeStyle Libre 2 App Receives FDA Clearance


On August 2, 2021, the FDA approved the FreeStyle Libre 2 app for adults and children with diabetes, allowing user to access glucose readings directly from their iPhone.MORE
Senza

FDA Approves Senza®, Nevro’s High Frequency Spinal Cord Stimulation Therapy For PDN


The Senza System has been approved by the FDA for the treatment of chronic pain associated with painful diabetic neuropathy.MORE
Semglee

Semglee Receives FDA Approval as First Interchangeable Biosimilar Insulin


Semglee becomes the first interchangeable biosimilar insulin product for the treatment of type 1 and type 2 diabetes.MORE
Culturally Sensitive LGBTQ+ Diabetes Health Care

Providing Culturally Sensitive LGBTQ+ Diabetes Health Care


Culturally sensitive LGBTQ+ diabetes health care can decrease stigma and advance diabetes care access for the LGBTQ community. MORE
Black Mother With Type 1 Diabetes

High Risk Pregnancy – Mitigating Risks for Type 1 Diabetes + Black Maternal Health Outcomes


Ariel Lawrence, a diabetes advocate and Black mother with type 1 diabetes, shares how she navigated her pregnancy. MORE
disparities in pediatric diabetes

Addressing Disparities in Pediatric Diabetes Treatment In Philadelphia


Terri Lipman shares how incorporating community health workers can tackle disparities in pediatric diabetes treatment. MORE
teplizumab

FDA Issues CRL for Teplizumab, Investigational Candidate to Delay the Onset of T1D


The FDA issues a complete response letter to Provention Bio as part of an update for Teplizumab to delay the onset of type 1 diabetes.MORE

Combating Diabetes Disparities Among The Hispanic Population


At ADA 2021, David Marrero discusses how culturally tailored care can combat diabetes disparities among the Hispanic population.MORE
walmart

Walmart Launches Lower-Cost Analog Insulin: ReliOn NovoLog


ReliOn NovoLog will be available at Walmart and Sam's Club pharmacies for $72.88 per vial and $85.88 per box of five FlexPens.MORE
depression among african american

Preliminary Findings On Depression Among African American and Latino Parents of Children With T1D


Samantha Carreon shares preliminary data on the TEAM study which found higher rates of depression among African American and Latino parents.MORE
JP Qualters

Making Broadway More Accessible With JP Qualters


JP Qualters shares his experience on Broadway as a person living with type 1 diabetes and his aspirations for the theater industry.MORE
Zegalogue®

Zegalogue® Is Now Commercially Available In The United States


Zegalogue®, also known as dasiglucagon, is now commercially available in the U.S. for the treatment of severe hypoglycemia.MORE
continuous glucose monitor coverage

Medicare Loosens Restrictions on Continuous Glucose Monitor Coverage


Medicare revised its local coverage determination policy to remove requirements for continuous glucose monitor coverage.MORE
ACA intact

Supreme Court Votes To Keep The ACA Intact


The Affordable Care Act (ACA) provides health care to millions of Americans. The Supreme Court voted 7-2 to keep the ACA intact.MORE
vaccine access

COVID-19 Vaccines And Diabetes: Vaccine Access Issues For People Of Color


Communities of color with diabetes face a myriad of barriers when it comes to vaccine access. Experts share how the U.S. can achieve vaccine equity.MORE
diabetes program accessibility

Michelle L. Litchman Focuses On Diabetes Program Accessibility For People Who Are Deaf


Michelle L. Litchman was named a Betty Irene Moore Nurse Fellow. She will focus on diabetes program accessibility for people who are deaf.MORE

Test Strip Subscription Guide


We compiled a rundown of popular companies that offer test strip subscription services and researched each of them to give you some important info.MORE
omnipod 5

Omnipod 5 Pivotal Trial Data Published


Data from the pivotal trial shows that the Omnipod 5 improves time-in-range, and reduces HbA1c and mean glucose levels. MORE
ATTD 2021

Breaking News From ATTD 2021


This year, ATTD 2021 will be held virtually where developers and clinicians will present their new diabetes technology and research.MORE
mental health

Survey Finds the Pandemic Increased Mental Health Concerns Among People With Diabetes


Cecelia Health conducted a survey that revealed increased mental health concerns among people with diabetes during the COVID-19 pandemic. MORE
teplizumab

FDA Advisory Committee Votes 10-7 To Recommend Approval of Teplizumab For Delay Of Type 1 Diabetes


Teplizumab is an investigational candidate proven to delay the onset of type 1 diabetes. The FDA advisory committee reviews its efficacy.MORE
bullying

Combating Bullying: How One Person With Diabetes Fought To Test Her Blood Sugar In The Workplace


Sheri Byrne shares her experience on how she fought workplace bullying due to diabetes and advocated for herself.MORE
Bigfoot Unity

Bigfoot Unity™ Diabetes Management System Receives The Green Light From The FDA


Bigfoot Unity™, a one-of-a-kind diabetes management system with smart pen caps received FDA approval on May 10, 2021 and will reach select diabetes clinics this spring. MORE

Asian Isn’t A Monolith: Why More Specific Data Matters in Diabetes Research


Data on how diabetes impacts specific ethnic groups could help us better support people within Asian American Pacific Islander communities.MORE
ramadan

Type 1 Diabetes + Ramadan: Here’s How a Few People Are Observing


People with diabetes face their own set of challenges when observing Ramadan. Two people with diabetes share their experiences. MORE

The PROTECT Study 


The PROTECT Study aims to understand how the investigational medicine, teplizumab, works in children and young adults who have recently been diagnosed with T1D, as well as assessing if there are any s...MORE
aapi diabetes research

Chris Hahm’s Uphill Battle: The Severe Underfunding of AAPI Diabetes Research


H. Chris Hahm shares her challenges of conducting diabetes research focused on the AAPI community, research that is severely underfunded.MORE

CDC and FDA Call for Pause on Johnson & Johnson Vaccine


After six cases of rare blood clots, the CDC and FDA has advised healthcare professionals to pause on distributing the Johnson and Johnson vaccine.MORE

FDA Approves New Glucagon Option from Zealand Pharma


Available in June 2021, the FDA approved Zealand Pharma’s Zeagalogue, a new form of glucagon for people with insulin-dependent diabetes.MORE
ADA Collab

Two Pillars in the Diabetes Community Unite to Serve Millions Living with Diabetes


The partnership will feature combined resources, strategies, and tactics to better serve people living with type 1 diabetes, type 2 diabetes, and prediabetes.MORE

JDRF Announces New Center of Excellence to Advance T1D Research


On February 23, 2021, JDRF announced the launch of the JDRF Center of Excellence in collaboration with the Harvard Stem Cell Institute in New England.MORE

Get the Facts on Insulin Pricing + The Presidential Transition


A flurry of misinformation is stoking fears that the Biden Admin paused or reversed a previous Trump Admin policy that lowered the price of insulin. MORE

New Year, New Administration: What’s Coming For US Healthcare Policy


With a new governmental administration, it is likely we will see notable and impactful movement in healthcare policy. What can we expect? MORE

Congress Renews Funding for Special Diabetes Program


On Dec 22, 2020, Congress renewed the Special Diabetes Program, providing $150 million annually in type 1 diabetes research funding until 2023MORE

JDRF Launches Program to Advance Universal Screening for Type 1 Diabetes


T1Detect is a new screening initiative designed to make early detection of type 1 diabetes easier and more accessible to a broad population. MORE

Diabetes + COVID Vaccines: What You Need to Know


If you have diabetes, here’s everything you need to know about the COVID-19 vaccines.MORE

Amazon Launches Online Pharmacy


Amazon Pharmacy, launched on November 17, delivers medications and prescription refills - such as insulin - with Prime membership 2-day shipping.MORE

Fourth Major Insulin Manufacturer Enters US Market with Semglee Launch


Semglee (insulin glargine), from Mylan and Biocon, is now available by prescription in the United States in vial and pre-filled pen presentations.MORE

With SAG-AFTRA Healthcare Changes, Can T1Ds Stay in the Arts?


With recently announced SAG-AFTRA healthcare changes, do the majority of people with T1D realistically have the option to choose a profession in the arts? MORE

JDRF Announces Updated Strategy, Renewed Focus in Light of COVID-19


Amidst COVID-19, JDRF prioritizing work in their portfolio that they see as having the highest likelihood for cures and life changing advances for diabetes.MORE

Study Links COVID-19 to Increased Rates of DKA at Diagnosis in Children


In a German study from March to May 2020, nearly half of minors had DKA at type 1 diabetes diagnosis - double previous years - amidst COVID-19.MORE

United Healthcare to Begin Covering Tandem Insulin Pumps


On July 1, 2020, United Healthcare (UHC) announced they will begin covering the Tandem t:slim X2 insulin pump, a departure from UHC’s four-year policy to only provide health insurance coverage for M...MORE

Preventing and Delaying Type 1 Diabetes: Updates From the Teplizumab Trial


Half of those treated with teplizumab remain diabetes-free, compared to 22% of those taking placebo, and the delay in diabetes onset was close to 3 years.MORE

Disparities in Diabetes and Diabetes Care—What Can We Do About It?


At this ADA 2020 session, systemic racism and implicit bias were clear contributors to poor health and healthcare outcomes for Black and Latinx communities.MORE

T1D Exchange + Beyond Type 1 Marathon Study Presented at ADA 2020


The Beyond Type Run team has taken on 26.2 miles to not only raise awareness and funds for T1D, but to provide crucial data for a study pertaining to management of Type 1 before, during, and after a m...MORE

One Drop Announces New Overnight Hypo Predictions and Long-Term Health Forecasts at ADA 2020


One Drop unveiled new AI-powered predictions for blood glucose, A1C, blood pressure, and weight up to six months in advanceMORE

FreeStyle Libre 2 Approved for Use in U.S.


Those living with type 1 diabetes in the U.S. now have the opportunity to manage their disease utilizing the perks of Abbott’s Freestyle Libre 2. MORE

Closed Loop Updates: Omnipod Horizon and Medtronic 780G data presented at ADA 2020


Data from four new clinical trials involving Hybrid Closed Loop systems, Medtronic 780G and Omnipod 5 Powered by Horizon was presented at ADA 2020.MORE

New Research Resource from Beyond Type 1 Aims to Bridge the Gap Between Science and Community


A new collection of resources shared today by Beyond Type 1 breaks down the most impactful current type 1 diabetes research into quick and easy to understand information. MORE

Medicare Part D Senior Savings Model Caps Insulin Costs at $35 per Month


The Senior Savings Model caps out of pocket insulin costs at $35 per month for seniors enrolled in eligible plans.MORE

England’s NHS Releases Study on Risk of COVID-19 for People with Diabetes


This week, the National Health Service (NHS) in England released the first study of its kind, breaking down COVID-19 mortality risk by type of diabetes.MORE

Armed For Diabetes Created to Help Veterans With Resources For Better Diabetes Management


Armed for Diabetes highlights continuous glucose monitoring prescribing guidelines for veterans.MORE

Roche Offers Free Access to mySugr Pro During COVID-19


With the rise of telemedicine during COVID-19, free access to mySugr Pro will help people stay connected to their healthcare team. MORE

Minnesota Passes the Alec Smith Insulin Affordability Act


The Alec Smith Insulin Affordability Act was signed into law in Minnesota, providing MN residents options for emergency and ongoing insulin access for those who qualify.MORE

Novo Offers Free 90-Day Insulin Supply to People Recently Uninsured Due to COVID-19


Novo Nordisk announces program offering a free 90-day supply of Novo Nordisk insulin for those who have recently lost their health insurance coverage due to a change in job status because of COVID-19....MORE

Beyond Type 1 Asks Congress To Support Expanded Paid Leave For Chronic Conditions During COVID-19


Beyond Type 1 joined 156 other organizations in urging Congress to expand paid leave for those with chronic illness, who are at higher risk for complications from COVID-19.MORE

FreeStyle Libre Approved by FDA for Hospitalized Patients During COVID-19 Pandemic


Abbott's FreeStyle Libre 14 day system will allow doctors to remotely monitor their patient's glucose levels. MORE